Fudosteine

Drug Profile

Fudosteine

Alternative Names: Cleanal; Spelear; SR 320; SS 320; SS 320A

Latest Information Update: 09 Jan 2008

Price : $50

At a glance

  • Originator Hisamitsu Pharmaceutical
  • Developer Mitsubishi Tanabe Pharma Corporation
  • Class Antitussives; Diamino amino acids; Dicarboxylic amino acids; Disulfides; Expectorants; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bronchitis; Cough

Most Recent Events

  • 01 Oct 2007 Mitsubishi Pharma Corporation has merged with Tanabe Seiyaku to form Mitsubishi Tanabe Pharma Corporation
  • 01 Apr 2005 SSP Co. has sold its ethical drugs business to Hisamitsu Pharmaceutical
  • 21 Jul 2004 Solution formulations of fudosteine have been launched in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top